{{Rsnum
|rsid=1341164
|Gene=CYP2C8
|Chromosome=10
|position=96800873
|Orientation=plus
|GMAF=0.2016
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=132
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 7.1 | 49.6 | 43.4
| HCB | 0.0 | 11.1 | 88.9
| JPT | 0.0 | 7.2 | 92.8
| YRI | 8.2 | 39.5 | 52.4
| ASW | 1.8 | 45.6 | 52.6
| CHB | 0.0 | 11.1 | 88.9
| CHD | 0.0 | 10.3 | 89.7
| GIH | 6.0 | 36.0 | 58.0
| LWK | 11.9 | 45.9 | 42.2
| MEX | 1.7 | 29.3 | 69.0
| MKK | 7.7 | 47.1 | 45.2
| TSI | 10.0 | 38.0 | 52.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1341164
|Name_s=rs1341164 T/C CYP2C8
|Gene_s=CYP2C8
|Feature=
|Evidence=PubMed ID:20157331
|Annotation=Risk or phenotype-associated allele: Not specified. Phenotype: This SNP was associated with clearance of docetaxel. Study size: 31. Study population/ethnicity: Patients with Non-Small-Cell Lung Carcinoma. Significance metric(s): p = 0.0097 (ANOVA); p = 0.0013 (QMIS); p = 0.0040 (KW) Type of association: PK.
|Drugs=docetaxel
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291804
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1341164
|overall_frequency_n=25
|overall_frequency_d=124
|overall_frequency=0.201613
|n_genomes=23
|n_genomes_annotated=0
|n_haplomes=26
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}